Skip to main content

Table 5 GLS (%) parameters per vessel

From: Two-dimensional speckle tracking for the assessment of coronary artery disease during dobutamine stress echo: clinical tool or merely research method

  LAD disease (+) LAD disease (−) p-value
Rest −21.86 ± 3.09 −23.20 ± 2.87 0.03
Peak dose −16.38 ± 5.76 −24.96 ± 4.42 <0.001
Delta −5.46 ± 5.27 1.76 ± 3.77 <0.001
  LCX disease (+) LCX disease (−)  
Rest −19.80 ± 3.16 −21.70 ± 2.88 0.01
Peak dose −16.13 ± 4.53 −23.43 ± 3.69 <0.001
Delta −3.59 ± 4.91 1.51 ± 4.14 <0.001
  RCA disease (+) RCA disease (−)  
Rest −18.73 ± 3.052 −20.23 ± 2.87 0.04
Peak dose −15.69 ± 5.96 −22.11 ± 4.21 <0.001
Delta −3.47 ± 5.22 1.65 ± 4.17 <0.001
  LCX-RCA disease (+) LCX-RCA disease (−)  
Rest −19.28 ± 2.10 −20.29 ± 2.33 0.03
Peak dose −16.43 ± 5.30 −22.42 ± 3.95 <0.001
Delta −2.83 ± 5.11 2.18 ± 3.95 <0.001